Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression

Journal of Molecular Cell Biology

Volumn 4, Issue 3, 2012, Pages 127-132

  Hirata, Yoshito ^a   Akakura, Koichiro ^b   Higano, Celestia S ^c   Bruchovsky, Nicholas ^d   Aihara, Kazuyuki ^a  

^a INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^b TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

androgen deprivation; biochemical relapse; classification; intermittent androgen suppression; mathematical model; optimal scheduling; prediction; prostate cancer

Indexed keywords

ANTIANDROGEN; ESTROGEN DERIVATIVE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CASTRATION; DRUG INTERMITTENT THERAPY; HUMAN; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PIECEWISE LINEAR MODEL; PROSTATE CANCER; REVIEW; TREATMENT DURATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; HUMANS; MALE; MODELS, THEORETICAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84861839115     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs020     Document Type: Review

References (38)

1. Aihara, K., and Suzuki, H. (2010). Theory of hybrid dynamical systems and its applications to biological and medical systems. Philos. Transact. A Math. Phys. Eng. Sci. 368, 4893-4914.
2. Akakura, K. (2005). Intermittent Endocrine Therapy for Prostate Cancer. Tokyo: Medical View (in Japanese).
3. Akakura, K., Bruchovsky, N., Goldenberg, S.L., et al. (1993). Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71, 2782-2790.
4. Attar, R.M., Takimoto, C.H., and Gottardis, M.M. (2009). Castration-resistant prostate cancer: locking up the molecular escape routes. Clin. Cancer Res. 15, 3251-3255.
5. Bruchovsky, N., Klotz, L., Crook, J., et al. (2006). Final results of the Canadian Prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107, 389-395.
6. Bruchovsky, N., Klotz, L., Crook, J., et al. (2007). Locally advanced prostate cancer: biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109, 858-867.
7. Bruchovsky, N., Klotz, K., Crook, J., et al. (2008). Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin. Genitourin Cancer 6, 46-52.
8. Chuu, C., Hiipakka, R.A., Fukuchi, J., et al. (2005). Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in a thymic mice. Cancer Res. 65, 2082-2084.
9. Dimonte, G. (2010). A cell kinetics model for prostate cancer and its application to clinical data and individual patients. J. Theor. Biol. 264, 420-442.
10. Eikenberry, S.E., Nagy, J.D., and Kuang, Y. (2010). The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol. Direct 5, 24.
11. Feldman, B.J., and Feldman, D. (2001). The development of androgenindependent prostate cancer. Nat. Rev. Cancer 1, 35-45.
12. Guo, Q., Tao, Y., and Aihara, K. (2008). Mathematical modelling of prostate tumor growth under intermittent androgen suppression with partial differential equations. Int. J. Bifurcat. Chaos 18, 3789-3797.
13. Higano, C.S., Shields, A., Wood, N., et al. (2004). Bone mineral density in prostate cancer patients without bone metastases who are treated with intermittent androgen suppression. Urology 64, 1182-1186.
14. Hirata, Y., Bruchovsky, N., and Aihara, K. (2010a). Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J. Theor. Biol. 264, 517-527.
15. Hirata, Y., di Bernardo, M., Bruchovsky, N., et al. (2010b). Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer. Chaos 20, 045125.
16. Hirata, Y., Tanaka, G., Bruchovsky, N., et al. (2012). Mathematically modeling and controlling prostate cancer under intermittent hormone therapy. Asian J. Androl. 14, 270-277.
17. Hu, R., Dunn, T.A., Wei, S., et al. (2008). Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22.
18. Huggins, C., and Hodges, C.V. (1941). Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297.
19. Ideta, A.M., Tanaka, G., Takeuchi, T., et al. (2008). A mathematical model of intermittent androgen suppression for prostate cancer. J. Nonlinear Sci. 18, 593-614.
20. Jackson, T.L. (2004a). A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 6, 679-704.
21. Jackson, T.L. (2004b). A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete Contin. Dyn. Syst.-Ser. B 4, 187-201.
22. Jain, H.V., Clinton, S.K., Bhinder, A., et al. (2011). Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proc. Natl Acad. Sci. USA 108, 19701-19706.
23. Klein, C.A. (2009). Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302-312.
24. Klotz, L.H., Herr, H.W., Morse, M.J., et al. (1986). Intermittent endocrine therapy for advanced prostate cancer. Cancer 58, 2546-2550.
25. Kokontis, J., Hay, N., and Liao, S. (1998). Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12, 941-953.
26. Kokontis, J., Hsu, S., Chuu, C., et al. (2005). Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65, 287-298.
27. Kronik, N., Kogan, Y., Elishmereni, M., et al. (2010). Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One 12, e15482.
28. Kuramae, H., Hirata, Y., Bruchovsky, N., et al. (2011). Nonlinear systems identification by combining regression with bootstrap resampling. Chaos 21, 043121.
29. Liberzon, D. (2003). Switching in Systems and Control. Boston: Birkhäuser.
30. Portz, T., Kuang, Y., and Nagy, J.D. (2012). A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy. AIP Adv. 2, 011002.
31. Rennie, P., Read, J., and Murphy, L. (2005). 'Hormones and cancer'. In: Tannock, I.F., Hill, R.P., Bristow, R.G., and Harrington, L. (eds). The Basic Science of Oncology. New York: McGraw-Hill, 400-430.
32. Shimada, T., and Aihara, K. (2008). A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. Math. Biosci. 214, 134-139.
33. Suzuki, T., Bruchovsky, N., and Aihara, K. (2010). Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer. Philos. Transact. A Math. Phys. Eng. Sci. 368, 5045-5059.
34. Tanaka, G., Tsumoto, K., Tsuji, S., et al. (2008). Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer. Physica D 237, 2616-2627.
35. Tanaka, G., Hirata, Y., Goldenberg, S.L., et al. (2010). Mathematical modeling of prostate cancer growth and its application to hormone therapy. Philos. Transact. A Math. Phys. Eng. Sci. 368, 5029-5044.
36. Tao, Y., Guo, Q., and Aihara, K. (2009). A model at the macroscopic scale of prostate tumor growth under intermittent androgen suppression. Math. Models Meth. Appl. Sci. 19, 2177-2201.
37. Tao, Y., Guo, Q., and Aihara, K. (2010). A mathematical model of prostate tumor growth under hormone therapy with mutation inhibitor. J. Nonlinear Sci. 20, 219-240.
38. Yu, E.Y., Gulati, R., Telesca, D., et al. (2010). Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J. Clin. Oncol. 28, 2668-2673.